• Something wrong with this record ?

HER2 Status in Low-grade Serous Ovarian Tumors

K. Němejcová, A. Šafanda, M. Kendall Bártů, N. Hájková, J. Drozenová, P. Fabian, J. Laco, R. Matěj, G. Méhes, P. Škapa, I. Stružinská, P. Dundr

. 2025 ; 44 (4) : 331-335. [pub] 20240730

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25015236

Using immunohistochemistry, we examined a large cohort of 135 ovarian tumors, made up of 96 low-grade serous carcinomas (LGSCs) and 39 serous borderline tumors (micropapillary variant, mSBT), with the aim of exploring their HER2 status (overexpression). We followed with comprehensive genomic analyses on this sample set from our previous study, which revealed HER2 mutation in 5% (4/75) of LGSC and 10% (3/29) of mSBT. No cases were evaluated as HER2-positive, but 6 LGSCs and 1 mSBT were scored as HER2 1+, and 2 LGSCs and 1 mSBT showed the so-called HER2 "ultra-low" phenotype. This could be of clinical value as a potential therapeutical target concerning emerging therapeutic treatments (antibody conjugates). However, the clinical significance of this expression still needs to be established.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015236
003      
CZ-PrNML
005      
20250731090845.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/PGP.0000000000001059 $2 doi
035    __
$a (PubMed)39230502
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Němejcová, Kristýna $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
245    10
$a HER2 Status in Low-grade Serous Ovarian Tumors / $c K. Němejcová, A. Šafanda, M. Kendall Bártů, N. Hájková, J. Drozenová, P. Fabian, J. Laco, R. Matěj, G. Méhes, P. Škapa, I. Stružinská, P. Dundr
520    9_
$a Using immunohistochemistry, we examined a large cohort of 135 ovarian tumors, made up of 96 low-grade serous carcinomas (LGSCs) and 39 serous borderline tumors (micropapillary variant, mSBT), with the aim of exploring their HER2 status (overexpression). We followed with comprehensive genomic analyses on this sample set from our previous study, which revealed HER2 mutation in 5% (4/75) of LGSC and 10% (3/29) of mSBT. No cases were evaluated as HER2-positive, but 6 LGSCs and 1 mSBT were scored as HER2 1+, and 2 LGSCs and 1 mSBT showed the so-called HER2 "ultra-low" phenotype. This could be of clinical value as a potential therapeutical target concerning emerging therapeutic treatments (antibody conjugates). However, the clinical significance of this expression still needs to be established.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nádory vaječníků $x patologie $x genetika $x metabolismus $7 D010051
650    12
$a serózní cystadenokarcinom $x patologie $x genetika $x metabolismus $7 D018284
650    12
$a receptor erbB-2 $x genetika $x metabolismus $7 D018719
650    _2
$a imunohistochemie $7 D007150
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    _2
$a mutace $7 D009154
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a senioři $7 D000368
655    _2
$a časopisecké články $7 D016428
700    1_
$a Šafanda, Adam $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Kendall Bártů, Michaela $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Hájková, Nikola $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Drozenová, Jana $u Department of Pathology, Charles University, 3rd Faculty of Medicine, University Hospital Královské Vinohrady, Prague, Czech Republic
700    1_
$a Fabian, Pavel $u Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Laco, Jan $u The Fingerland Department of Pathology, Charles University Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic
700    1_
$a Matěj, Radoslav $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Department of Pathology, Charles University, 3rd Faculty of Medicine, University Hospital Královské Vinohrady, Prague, Czech Republic $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Méhes, Gábor $u Department of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
700    1_
$a Škapa, Petr $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Stružinská, Ivana $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Dundr, Pavel $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
773    0_
$w MED00002324 $t International journal of gynecological pathology $x 1538-7151 $g Roč. 44, č. 4 (2025), s. 331-335
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39230502 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090840 $b ABA008
999    __
$a ok $b bmc $g 2366224 $s 1252361
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 44 $c 4 $d 331-335 $e 20240730 $i 1538-7151 $m International journal of gynecological pathology $n Int J Gynecol Pathol $x MED00002324
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options